New drug aims to cut blood transfusions for rare bone marrow disorder
NCT ID NCT05732961
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 34 times
Summary
This study tests if luspatercept can help people with certain types of MDS or MDS/MPN need fewer blood transfusions for anemia. Six adults with low- or intermediate-risk disease and a specific gene mutation are receiving the drug plus standard care. The goal is to see if they can go without transfusions for a period and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.